| Literature DB >> 21665566 |
Cheryl R Stein1, David A Savitz.
Abstract
BACKGROUND: Perfluorinated compounds (PFCs) are persistent environmental pollutants. Toxicology studies demonstrate the potential for perfluorooctanoic acid (PFOA) and other PFCs to affect human growth and development. Attention deficit/hyperactivity disorder (ADHD) is a developmental disorder with suspected environmental and genetic etiology.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21665566 PMCID: PMC3230446 DOI: 10.1289/ehp.1003538
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Univariate characteristics of non-Hispanic white children 5–18 years of age, C8 Health Project, Mid-Ohio Valley, 2005–2006 (n = 10,546).
| Characteristic | Measure |
|---|---|
| ADHD diagnosis | |
| Yes | 1,303 (12.4) |
| No | 9,243 (87.6) |
| ADHD diagnosis + medication | |
| Yes | 542 (5.1) |
| No | 10,004 (94.9) |
| Learning problem | |
| Yes | 1,281 (12.1) |
| No | 9,265 (87.9) |
| Serum PFOA (ng/mL) | 66.3 ± 106.1 |
| Quartile 1: 0.6 to < 13.0 | 2,643 (25.1) |
| Quartile 2: 13.0 to < 28.2 | 2,634 (25.0) |
| Quartile 3: 28.2 to < 65.3 | 2,643 (25.1) |
| Quartile 4: 65.3 to 2070.6 | 2,626 (24.9) |
| Serum PFOS (ng/mL) | 22.9 ± 12.5, |
| Quartile 1: 0.25 to < 14.8 | 2,597 (24.6) |
| Quartile 2: 14.8 to < 20.2 | 2,655 (25.2) |
| Quartile 3: 20.2 to < 27.9 | 2,632 (25.0) |
| Quartile 4: 27.8 to 202.1 | 2,662 (25.2) |
| Serum PFHxS (ng/mL) | 9.3 ± 13.7 |
| Quartile 1: 0.25 to < 2.9 | 2,716 (25.7) |
| Quartile 2: 2.9 to < 5.2 | 2,500 (23.7) |
| Quartile 3: 5.2 to < 10.1 | 2,689 (25.5) |
| Quartile 4: 10.1 to 276.4 | 2,641 (25.0) |
| Serum PFNA (ng/mL) | 1.7 ± 1.0 |
| Quartile 1: 0.25 to < 1.2 | 2,552 (24.2) |
| Quartile 2: 1.2 to < 1.5 | 2,387 (22.6) |
| Quartile 3: 1.5 to < 2.0 | 2,880 (27.3) |
| Quartile 4: 2.0 to 24.1 | 2,727 (25.9) |
| Sex | |
| Male | 5,446 (51.6) |
| Female | 5,100 (48.4) |
| Age (years) | 13.1 ± 3.8 |
| Quintile 1: 5.0 to < 9.3 | 2,092 (19.8) |
| Quintile 2: 9.3 to < 12.3 | 2,099 (19.9) |
| Quintile 3: 12.3 to < 14.7 | 2,116 (20.1) |
| Quintile 4: 14.7 to < 16.8 | 2,129 (20.2) |
| Quintile 5: 16.8 to < 19.0 | 2,110 (20.0) |
| Average household income | |
| ≤ $30,000 | 3,968 (47.8) |
| > $30,000 | 4,335 (52.2) |
| BMI (kg/m2) | 21.9 ± 5.5 |
| BMI | 0.5 ± 1.3 |
| BMI percentile | |
| Underweight (< 5th) | 440 (4.4) |
| Healthy weight (5th to < 85th) | 5,801 (58.6) |
| Overweight (85th to < 95th) | 1,686 (17.0) |
| Obese (> 95th) | 1,973 (19.9) |
| Single water district | |
| Yes | 2,437 (37.4) |
| No | 4,086 (62.6) |
| Data are presented as | |
Crude and adjusteda associations between serum PFC exposure and ADHD or learning problemsb among children 5–18 years of age, C8 Health Project, Mid-Ohio Valley, 2005–2006 (n = 10,546).
| ADHD diagnosis | ADHD diagnosis + medication | Learning problem | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum PFC (ng/mL) | No. of cases | Crude OR | Adjusted OR (95% CI) | No. of cases | Crude OR | Adjusted OR (95% CI) | No. of cases | Crude OR | Adjusted OR (95% CI) | |||||||||
| PFOA | ||||||||||||||||||
| Quartile 1: 0.6 to < 13.0 | 327 | 1.00 | 1.00 | 129 | 1.00 | 1.00 | 326 | 1.00 | 1.00 | |||||||||
| Quartile 2: 13.0 to < 28.2 | 364 | 1.14 | 1.10 (0.94–1.30) | 159 | 1.25 | 1.20 (0.94–1.53) | 318 | 0.98 | 0.95 (0.81–1.12) | |||||||||
| Quartile 3: 28.2 to < 65.3 | 337 | 1.04 | 0.98 (0.83–1.15) | 146 | 1.14 | 1.04 (0.81–1.32) | 330 | 1.01 | 0.98 (0.83–1.15) | |||||||||
| Quartile 4: 65.3 to 2070.6 | 275 | 0.83 | 0.76 (0.64–0.90) | 108 | 0.84 | 0.72 (0.55–0.94) | 307 | 0.94 | 0.90 (0.76–1.06) | |||||||||
| PFOS | ||||||||||||||||||
| Quartile 1: 0.25 to < 14.8 | 299 | 1.00 | 1.00 | 107 | 1.00 | 1.00 | 347 | 1.00 | 1.00 | |||||||||
| Quartile 2:14.8 to < 20.2 | 321 | 1.06 | 0.99 (0.83–1.17) | 134 | 1.24 | 1.15 (0.89–1.50) | 317 | 0.88 | 0.83 (0.70–0.98) | |||||||||
| Quartile 3: 20.2 to < 27.9 | 318 | 1.06 | 0.96 (0.81–1.14) | 137 | 1.28 | 1.14 (0.87–1.48) | 288 | 0.80 | 0.74 (0.62–0.87) | |||||||||
| Quartile 4: 27.8 to 202.1 | 365 | 1.22 | 1.09 (0.93–1.29) | 164 | 1.53 | 1.27 (0.99–1.64) | 329 | 0.91 | 0.85 (0.72–1.00) | |||||||||
| PFHxS | ||||||||||||||||||
| Quartile 1: 0.25 to < 2.9 | 258 | 1.00 | 1.00 | 89 | 1.00 | 1.00 | 300 | 1.00 | 1.00 | |||||||||
| Quartile 2: 2.9 to < 5.2 | 304 | 1.32 | 1.27 (1.06–1.52) | 128 | 1.59 | 1.44 (1.09–1.90) | 313 | 1.15 | 1.13 (0.95–1.34) | |||||||||
| Quartile 3: 5.2 to < 10.1 | 364 | 1.49 | 1.43 (1.21–1.70) | 157 | 1.83 | 1.55 (1.19–2.04) | 332 | 1.13 | 1.12 (0.95–1.33) | |||||||||
| Quartile 4: 10.1 to 276.4 | 377 | 1.59 | 1.53 (1.29–1.83) | 168 | 2.01 | 1.59 (1.21–2.08) | 336 | 1.17 | 1.19 (1.00–1.41) | |||||||||
| PFNA | ||||||||||||||||||
| Quartile 1: 0.25 to < 1.2 | 311 | 1.00 | 1.00 | 112 | 1.00 | 1.00 | 352 | 1.00 | 1.00 | |||||||||
| Quartile 2: 1.2 to < 1.5 | 302 | 1.04 | 1.00 (0.84–1.19) | 117 | 1.12 | 1.02 (0.78–1.34) | 299 | 0.89 | 0.87 (0.74–1.03) | |||||||||
| Quartile 3: 1.5 to < 2.0 | 349 | 0.99 | 0.94 (0.79–1.11) | 151 | 1.21 | 1.06 (0.82–1.36) | 340 | 0.84 | 0.81 (0.69–0.95) | |||||||||
| Quartile 4: 2.0 to 24.1 | 341 | 1.03 | 0.99 (0.84–1.18) | 162 | 1.38 | 1.16 (0.90–1.49) | 290 | 0.74 | 0.74 (0.62–0.87) | |||||||||
Adjusteda associations [OR (95% CI)] between serum PFC exposure and ADHD or learning problemsb among children 12–15 years of age, C8 Health Project, Mid-Ohio Valley, 2005–2006 (n = 3,571).
| Serum PFC (ng/mL) | ADHD diagnosis | ADHD diagnosis + medication | Learning problem | |||
|---|---|---|---|---|---|---|
| PFOA | ||||||
| Quartile 1: 0.6 to < 13.0 | 1.00 | 1.00 | 1.00 | |||
| Quartile 2: 13.0 to < 28.2 | 1.18 (0.91–1.53) | 1.39 (0.95–2.04) | 1.13 (0.86–1.47) | |||
| Quartile 3: 28.2 to < 65.3 | 0.93 (0.71–1.21) | 1.25 (0.85–1.83) | 0.93 (0.71–1.21) | |||
| Quartile 4: 65.3 to 2070.6 | 0.79 (0.60–1.04) | 0.87 (0.58–1.32) | 0.96 (0.73–1.26) | |||
| PFOS | ||||||
| Quartile 1: 0.25 to < 14.8 | 1.00 | 1.00 | 1.00 | |||
| Quartile 2:14.8 to < 20.2 | 0.91 (0.70–1.19) | 1.40 (0.94–2.08) | 0.78 (0.60–1.01) | |||
| Quartile 3: 20.2 to < 27.9 | 0.92 (0.71–1.21) | 1.38 (0.92–2.06) | 0.68 (0.52–0.89) | |||
| Quartile 4: 27.8 to 202.1 | 0.99 (0.76–1.30) | 1.32 (0.88–1.99) | 0.71 (0.54–0.93) | |||
| PFHxS | ||||||
| Quartile 1: 0.25 to < 2.9 | 1.00 | 1.00 | 1.00 | |||
| Quartile 2: 2.9 to < 5.2 | 1.46 (1.10–1.93) | 1.32 (0.87–1.99) | 1.31 (1.00–1.71) | |||
| Quartile 3: 5.2 to < 10.1 | 1.45 (1.10–1.91) | 1.32 (0.88–1.97) | 1.08 (0.82–1.43) | |||
| Quartile 4: 10.1 to 276.4 | 1.53 (1.15–2.04) | 1.42 (0.94–2.13) | 1.05 (0.79–1.40) | |||
| PFNA | ||||||
| Quartile 1: 0.25 to < 1.2 | 1.00 | 1.00 | 1.00 | |||
| Quartile 2: 1.2 to < 1.5 | 1.16 (0.89–1.51) | 1.12 (0.76–1.64) | 0.97 (0.74–1.25) | |||
| Quartile 3: 1.5 to < 2.0 | 0.96 (0.74–1.24) | 0.99 (0.67–1.45) | 0.86 (0.66–1.11) | |||
| Quartile 4: 2.0 to 24.1 | 1.00 (0.75–1.32) | 1.15 (0.78–1.71) | 0.73 (0.55–0.98) | |||